Advarra presents free clinical research resources during COVID-19 crisis

By Jenni Spinner

- Last updated on GMT

(Image: Getty/monsatj)
(Image: Getty/monsatj)

Related tags Clinical trial COVID-19 Coronavirus Data management

The research consulting and solutions provider will offer complimentary transfer of IRB oversight, access to eRegulatory software and more.

In response to the unique, unprecedented challenges the COVID-19 pandemic has put upon the clinical research industry, Advarra has made several resources available to the community at no charge. In offering up the tools for free, the company said it hopes to alleviate burdens, clear obstacles and provide readily available guidance on issues caused by the virus.

The complimentary resources offered by the Columbia, MD-based company include free-of-charge transfer of institutional review board (IRB) services, access to an updated version of its Forte eRegulatory management software, its streamlined eReg software, and 'Ask Advarra' repository for guidance on emerging concerns brought about by COVID-19 developments.

Helpful gesture

Scott Uebele, Advarra CFO, told Outsourcing-Pharma that because the company’s mission focuses on advancing human health, offering these resources to the clinical research industry is both a needed action and a gesture of goodwill.

This is the moment to dig in and help out​,” he said. “Advarra subject matter experts—from IRB chairs and infectious disease specialists, to regulatory consultants and gene therapy experts—have been able to address each unique question submitted from the research community through our Ask Advarra page.​”

Uebele added that the company is loading the information about COVID-19 on its centralized Coronavirus Guidance webpage, so that it can be shared widely to aid researchers.

Benefiting the industry

Uebele told us the free resources potentially can benefit researchers, their institutions, sponsors and contract research organizations (CROs), whether they are chasing solutions for COVID-19 or are concerned by the virus’s potential impact on other projects.

Our hope is that all people will benefit from our help in enabling research to move forward​,” he said. “The free transfer of oversight can be seen as a temporary solution for studies impacted by local IRBs that are hampered by campus closures or central IRBs who lack virtual and telework capabilities since Advarra has remained fully operational​.

Uebele also said that when the industry has returned to normalcy after the current crisis, users that have transferred IRB oversight will be able to transfer studies back, if they opt to.

Robann Cunningham, Advarra’s chief commercial officer, said the company had noted an uptick in the amount of COVID-19-related research they had been reviewing, but wanted to do more.

COVID-19 has not adversely impacted Advarra’s business thanks to our virtual capabilities, and we feel it is our responsibility to give back since we have the expertise, depth of resources, and technology to keep research moving forward during these challenging times​,” she said.

Offered resources

The resources Advarra is offering during the COVID-19 crisis include:

  • Transfer of IRB oversight: to prevent the need to close studies, the company is offering free transfer to the end of 2020.
  • eReg Lite: the free version of its eRegulatory software also will be available until the end of the year.
  • Support and online resources: these include the Ask Advarra online forum and dedicated Coronavirus Guidance webpage.
  • Virtual support and counseling: the company is offering the help of its specialized staff to sponsors, CROs and sites.

In addition to the above-mentioned resources, the company is offering a COVID-19 webinar on Thursday, April 16. The online event will feature presentations from various institutions and the company’s leadership.

Related news

Show more

Related products

show more

Saama accelerates data review processes

Saama accelerates data review processes

Content provided by Saama | 25-Mar-2024 | Infographic

In this new infographic, learn how Saama accelerates data review processes. Only Saama has AI/ML models trained for life sciences on over 300 million data...

More Data, More Insights, More Progress

More Data, More Insights, More Progress

Content provided by Saama | 04-Mar-2024 | Case Study

The sponsor’s clinical development team needed a flexible solution to quickly visualize patient and site data in a single location

Using Define-XML to build more efficient studies

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Related suppliers

Follow us


View more